Transthyretin Amyloidosis, or ATTR, is considered a single disease, however the diversity in its clinical presentation is staggering. In this blog, we’ll discuss some of the most common hereditary variants and how the disease manifestation differs around the world in documented hotspots.
2022: Mackenzie’s Mission – Our Report Card
This past year was more of the same, but hitting a big milestone! With the help of so many, we continued to advance our dual mission of raising awareness and supporting research. Since we began …. For our raising awareness initiative – the Amyloidosis Speakers Bureau – we are SUPER PROUD to say we’ve given over 215 presentations to MORE THAN 10,000 medical students and residents!! For our supporting research initiative, we’ve given over $830,000!! Looking ahead, it’s all about continuing to do more of the same great work. We can’t do it without your support, passion, and shared determination to make a difference in the fight against amyloidosis. Thank you!
CRISPR/Cas9 – ATTR Clinical Trial Update
Per the National Institute of Health, “One of the most promising areas of research in recent years has been gene editing, including CRISPR/Cas9, for fixing misspellings in genes to treat or even cure many conditions.” In this piece we provide a clinical trial update for transthyretin (TTR) amyloidosis using this technology.
